Last updated: September 3, 2026
Orlynvah, the fixed-dose combination of sulopenem etzadroxil and probenecid, is Iterum Therapeutics’ first commercial product and the first oral penem antibiotic approved in the United States. The FDA approved it on October 25, 2024, for adult women with uncomplicated urinary tract infections caused by susceptible microorganisms when alternative oral antibacterial treatments are not feasible because of resistance or intolerance.[1]
The commercial opportunity is strategically important but structurally constrained. Orlynvah competes against inexpensive generic antibiotics, carries a stewardship-limited label, and is initially dependent on hospital, infectious-disease and payer adoption. Iterum’s financial trajectory therefore depends less on broad UTI volume than on its ability to establish Orlynvah as a reserve oral treatment for resistant infections.
What is sulopenem etzadroxil and how does probenecid affect the product?
Sulopenem etzadroxil is an orally administered prodrug converted to sulopenem, a penem antibacterial. Probenecid slows renal tubular secretion of sulopenem, increasing and prolonging systemic exposure.[1]
Orlynvah is supplied as 500 mg sulopenem etzadroxil and 500 mg probenecid tablets. The FDA-approved regimen is one tablet twice daily with food for five days.[1]
| Product attribute |
Orlynvah |
| Active ingredients |
Sulopenem etzadroxil and probenecid |
| Dosage form |
Oral tablet |
| FDA approval |
October 25, 2024 |
| Sponsor |
Iterum Therapeutics plc |
| Initial indication |
Uncomplicated urinary tract infection in adult women |
| Treatment duration |
Five days |
| FDA pathway |
New drug application |
| Regulatory designation |
Qualified Infectious Disease Product and priority review eligibility |
| Commercial status |
U.S. launch product |
Probenecid is not commercially novel by itself. It is a long-established generic uricosuric drug also used to alter renal elimination of selected medicines. The commercial and patent value resides in the combination, formulation, pharmacokinetic use and sulopenem-related intellectual property, not in probenecid as a standalone molecule.
What FDA regulatory status does Orlynvah have?
The FDA approved Orlynvah under NDA 215814 for uncomplicated urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Enterobacter cloacae complex.[1]
The label restricts use when alternative oral antibacterial treatments are not feasible. This wording materially limits first-line prescribing. Physicians are expected to use established agents when susceptible organisms can be treated with nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin, fluoroquinolones or other appropriate therapies.
The product received QIDP treatment under the Generating Antibiotic Incentives Now provisions of the FDA Safety and Innovation Act. QIDP status can provide priority review and additional regulatory protections, but it does not eliminate commercial barriers or create automatic formulary access.[1,2]
What clinical evidence supports sulopenem etzadroxil?
Iterum’s Phase 3 SURE-1 trial compared oral sulopenem etzadroxil-probenecid with oral ciprofloxacin in women with uncomplicated UTI. Sulopenem met the FDA-defined noninferiority standard in the microbiological intent-to-treat population, while showing activity against pathogens resistant to fluoroquinolones.[3]
The clinical positioning is therefore specific:
- It is an oral option for patients with resistant uropathogens.
- It may reduce reliance on intravenous carbapenems in selected cases.
- It is not positioned as a replacement for inexpensive first-line UTI antibiotics.
- Its value is highest when resistance eliminates conventional oral choices.
The product does not have an approved indication for complicated UTI, pyelonephritis, intra-abdominal infection, pneumonia or systemic infections. Any expansion into those markets would require additional clinical development and regulatory approval.
How large is the addressable market for Orlynvah?
The underlying U.S. uncomplicated UTI market is large, but the commercially addressable Orlynvah segment is much smaller. Most uncomplicated UTIs are treated with inexpensive generic antibiotics, and many patients do not require a reserve agent.
The relevant market can be divided into four segments:
| Segment |
Commercial relevance |
| Broad uncomplicated UTI |
Large patient volume, low price and high generic competition |
| Fluoroquinolone-resistant UTI |
Core target population |
| Extended-spectrum beta-lactamase and multidrug-resistant UTI |
High clinical value, but narrower volume |
| Patients unable to tolerate or access standard oral therapy |
Secondary target population |
Orlynvah’s market is therefore a high-value, low-volume model. The product must obtain coverage for cases where susceptibility testing or treatment history shows that standard oral agents are unsuitable.
Competitive products include:
- Nitrofurantoin, primarily generic;
- Trimethoprim-sulfamethoxazole, primarily generic;
- Fosfomycin, generic;
- Pivmecillinam, approved by the FDA in 2024 as Pivya;
- Fluoroquinolones, generic but subject to safety and resistance concerns;
- Intravenous carbapenems, used for severe or resistant infections;
- Other investigational oral beta-lactam and beta-lactamase inhibitor programs.
Pivmecillinam is the most relevant recent U.S. oral-antibiotic comparator because it also provides a new branded option in uncomplicated UTI. It is not a direct mechanistic substitute for Orlynvah in every resistant-infection setting, but payers and prescribers may evaluate the products within the same oral UTI treatment pathway.[4]
How does Orlynvah compare with generic antibiotics and Pivya?
| Factor |
Orlynvah |
Generic nitrofurantoin |
Generic TMP-SMX |
Pivya |
| Primary role |
Reserve oral treatment for resistant or unsuitable cases |
Common first-line therapy |
Common first-line therapy when susceptible |
Oral treatment for uncomplicated UTI |
| Price structure |
Branded specialty antibiotic |
Low generic cost |
Low generic cost |
Branded product |
| Resistance positioning |
Designed for organisms resistant to selected standard agents |
Limited by resistance and renal restrictions |
Resistance can be substantial |
Useful alternative, but susceptibility and patient factors apply |
| Treatment duration |
Five days, twice daily |
Usually five days |
Usually three days for uncomplicated UTI |
Five days |
| Main commercial barrier |
Restricted label and payer controls |
None material |
None material |
New-product access and competition |
| Biosimilar exposure |
None |
Not applicable |
Not applicable |
None |
Orlynvah’s pricing must overcome a substantial acquisition-cost differential. A branded reserve antibiotic can command a premium when it prevents hospitalization or intravenous therapy, but payers may impose prior authorization, step therapy or microbiology documentation.
What is the financial trajectory for Iterum Therapeutics?
Iterum entered commercialization with a single approved asset and without the diversified revenue base of a large pharmaceutical company. Before Orlynvah approval, the company’s financial profile was development-stage and dependent on equity financing, licensing transactions and capital-market access. FDA approval changed the company’s status but did not immediately create material product revenue.
The financial trajectory has four stages:
1. Pre-approval development financing
Before approval, Iterum funded sulopenem development through equity offerings, debt and strategic financing arrangements. The company’s principal asset was the sulopenem program, making clinical setbacks and regulatory delays material to valuation.[5]
2. Approval-driven value creation
The October 2024 approval reduced regulatory risk and created the possibility of commercial revenue. Approval also validated the oral sulopenem-probenecid formulation for a defined resistant-UTI population.
The approval did not solve:
- Commercial launch costs;
- Manufacturing scale-up;
- Sales-force requirements;
- Payer restrictions;
- Low initial prescribing volume;
- The company’s need for additional working capital.
3. Early-launch cash consumption
The first commercial period is likely to remain cash intensive. Iterum must fund market access, medical affairs, distribution, pharmacovigilance, inventory, sales operations and post-approval commitments before reaching a stable revenue run rate.
For a single-product antibiotic company, the central financial risk is the timing gap between product launch and reimbursement adoption. A product can be FDA approved and clinically differentiated while still producing limited near-term cash flow.
4. Revenue concentration and strategic optionality
Iterum’s revenue concentration is unusually high because Orlynvah is its principal commercial asset. The company’s medium-term options include:
- Direct commercialization in the United States;
- Regional licensing;
- Co-promotion;
- Development into additional infections;
- Expansion into complicated UTI or other resistant bacterial diseases;
- Acquisition by a larger anti-infective company.
The company’s financial upside is therefore asymmetric. Strong adoption in resistant UTI could support a meaningful commercial platform. Slow formulary adoption would leave Iterum dependent on financing or a partnering transaction.
What price and reimbursement factors affect Orlynvah revenue?
Orlynvah’s gross-to-net economics will be shaped by payer rebates, specialty-distribution fees, government discounts, copay support and institutional contracting. Gross sales can overstate the company’s realized revenue.
The product’s reimbursement case is strongest when the payer recognizes that an oral active agent may avoid:
- Emergency-department escalation;
- Hospital admission;
- Intravenous carbapenem treatment;
- Outpatient infusion;
- Treatment failure from an ineffective generic antibiotic.
The reimbursement case is weakest when the prescription is viewed as an expensive substitute for a susceptible, inexpensive generic.
Expected access controls include:
- Prior authorization for resistant organisms or treatment failure;
- Documentation that standard oral agents are unsuitable;
- Microbiology or susceptibility evidence;
- Quantity limits consistent with five-day treatment;
- Specialty-pharmacy or limited-distribution requirements in selected plans.
The commercial launch must also educate clinicians about probenecid-related contraindications and interactions. Probenecid can affect renal handling of other medicines and may create prescribing complexity compared with single-agent oral antibiotics.[1]
What patents protect sulopenem etzadroxil and Orlynvah?
Protection for Orlynvah is expected to rely on several categories rather than on probenecid itself:
- Sulopenem and sulopenem prodrug composition claims;
- Sulopenem etzadroxil formulations;
- Fixed-dose sulopenem etzadroxil-probenecid combinations;
- Pharmacokinetic enhancement using probenecid;
- Methods of treating bacterial infections;
- Solid-state, tablet and manufacturing claims.
The principal exclusivity risk is an ANDA with a Paragraph IV certification against listed patents. Because Orlynvah is a small-molecule drug, a generic applicant would use the ANDA pathway rather than the biosimilar pathway.
The FDA Orange Book is the controlling source for patents listed against NDA 215814. Listed patents can create a 30-month stay after timely patent litigation, while QIDP status may provide additional regulatory exclusivity separate from patent life.[2,6]
A commercial challenger would likely target:
- The fixed-dose combination;
- The use of probenecid to increase sulopenem exposure;
- Tablet formulation claims;
- Treatment methods for uncomplicated UTI;
- Manufacturing claims that are difficult to design around.
The estate is stronger if it combines composition, formulation, method-of-use and manufacturing claims. It is weaker if protection depends mainly on narrow treatment claims or claims that can be avoided through separate-tablet administration or a different formulation.
When does Orlynvah lose exclusivity?
The FDA-approved product benefits from multiple exclusivity layers:
| Exclusivity category |
Relevance |
| QIDP exclusivity |
Adds five years to applicable exclusivity for a qualifying antibacterial product |
| New chemical entity exclusivity |
Potentially relevant to the sulopenem etzadroxil product, subject to FDA determination of the applicable active moiety |
| Patent protection |
Depends on listed patent terms, patent-term adjustment and any patent-term extension |
| Pediatric exclusivity |
Could add six months if awarded after qualifying pediatric studies |
| Orphan exclusivity |
Not applicable to the current uncomplicated UTI indication |
A precise generic-entry date cannot be reduced to the approval date. It depends on the FDA’s Orange Book exclusivity entries, listed patent expiration dates, any patent-term extension, Paragraph IV litigation, settlement terms and the timing of ANDA approval.
The central legal question is whether a generic applicant can launch after patent expiry, after a settlement date, or at risk before the final patent date. Each scenario produces a different revenue curve.
Which companies are challenging Orlynvah?
No major public Paragraph IV challenge or settlement has established an early generic launch date for Orlynvah in the publicly available regulatory and litigation record cited here. The most credible future challengers are large generic manufacturers with UTI portfolios and the capacity to conduct bioequivalence, formulation and patent litigation work.
Potential challengers would evaluate:
- Whether the combination tablet is bioequivalent to the reference product;
- Whether probenecid is essential to the claimed pharmacokinetic effect;
- Whether a separate-component regimen can avoid formulation claims;
- Whether listed method-of-use patents are enforceable;
- Whether patent-term adjustment or extension materially delays launch.
What manufacturing and intellectual-property barriers affect supply?
Orlynvah requires reliable production of sulopenem etzadroxil, tablet formulation and combination-dose manufacturing. The supply chain is more complex than that of a mature generic antibiotic because Iterum must establish commercial-scale manufacturing, quality controls and inventory planning for a new product.
Potential manufacturing barriers include:
- Limited suppliers for sulopenem etzadroxil;
- Process know-how embedded in manufacturing patents;
- Validation requirements for the fixed-dose tablet;
- Stability and packaging requirements;
- Dependence on contract manufacturers;
- Low initial volume and unfavorable unit economics.
Manufacturing patents can delay generic entry even when a challenger designs around composition claims. They also increase the value of a licensing or acquisition transaction if the innovator controls a difficult-to-replicate process.
What generic launch scenarios exist for Orlynvah?
Scenario 1: Protected branded growth
Iterum secures payer coverage, uses microbiology-driven prescribing and retains exclusivity through the relevant patent and regulatory periods. Revenue grows gradually as resistance trends support reserve oral therapy.
Scenario 2: Restricted but durable niche
Orlynvah remains limited to infectious-disease specialists, hospitals and resistant UTI cases. Unit volume is modest, but net pricing and low direct competition support a specialized commercial business.
Scenario 3: Early Paragraph IV settlement
A generic applicant challenges the Orange Book patents and reaches a settlement with a launch date before the latest patent expiry. The settlement could cap long-term revenue while preserving several years of branded sales.
Scenario 4: At-risk generic launch
A generic company launches before final patent resolution. This would sharply reduce price and volume if the generic gains payer preference. The risk is highest if key patents are narrow or vulnerable to invalidity and noninfringement arguments.
How strong is the Orlynvah patent estate?
The estate has strategic value because the product combines a new oral penem prodrug with a pharmacokinetic enhancer. Combination, formulation and method-of-use claims can create layered protection.
Its practical strength depends on:
- Number and breadth of Orange Book-listed patents;
- Remaining patent term;
- Patent-term extension;
- Claim coverage of the marketed dose and tablet;
- Prior-art exposure;
- Availability of noninfringing alternative formulations;
- Whether generic applicants can separate sulopenem and probenecid components.
The estate should be viewed as potentially meaningful but not equivalent to the protection surrounding a biologic. Small-molecule antibiotics face ANDA competition, formulation workarounds and aggressive Paragraph IV litigation.
What is the commercial outlook for sulopenem etzadroxil?
The commercial outlook is positive on clinical differentiation but constrained on volume.
Upside drivers include:
- Rising antimicrobial resistance;
- Demand for oral alternatives to intravenous carbapenems;
- Limited new oral antibiotics;
- QIDP-related regulatory protection;
- High medical costs associated with treatment failure or hospitalization;
- Potential expansion into additional resistant bacterial infections.
Downside drivers include:
- Generic first-line UTI competition;
- Restrictive FDA label;
- Payer prior authorization;
- Limited prescriber familiarity;
- Probenecid drug-interaction concerns;
- Single-product revenue concentration;
- Capital requirements during launch;
- Potential future Paragraph IV litigation.
The most likely commercial model is a focused anti-infective product with premium pricing and low-to-moderate prescription volume, rather than a broad primary-care UTI blockbuster.
Key Takeaways
- Orlynvah is the branded combination of sulopenem etzadroxil and probenecid, approved by the FDA in October 2024.
- Its core value is activity against selected resistant pathogens when standard oral antibiotics are unsuitable.
- Probenecid improves sulopenem exposure but is an old generic drug and does not independently create substantial product value.
- Iterum’s revenue trajectory depends on market access, specialist adoption and evidence that Orlynvah avoids intravenous therapy or hospitalization.
- Generic competition will proceed through the ANDA and Paragraph IV pathways, not biosimilar litigation.
- Patent protection is likely to rely on sulopenem, prodrug, fixed-dose formulation, pharmacokinetic and method-of-use claims.
- The commercial opportunity is high value per treated patient but materially narrower than the overall uncomplicated UTI market.
- Iterum’s financial risk remains high because Orlynvah is its principal commercial asset and launch costs precede meaningful product revenue.
- The principal valuation catalysts are prescription growth, payer coverage, licensing or co-promotion, indication expansion and patent durability.
FAQs
Is probenecid itself a new drug in Orlynvah?
No. Probenecid is an established generic drug. The innovation is the fixed-dose combination with sulopenem etzadroxil and the use of probenecid to increase sulopenem exposure.
Is Orlynvah a carbapenem?
Sulopenem is a penem antibiotic related to the carbapenem class. Orlynvah is administered orally, unlike many commercially important carbapenems that require parenteral delivery.
Can a generic company file an ANDA for Orlynvah?
Yes. Orlynvah is a small-molecule drug. A qualifying generic applicant would generally use the ANDA pathway and may file Paragraph IV certifications against listed patents.
Does Orlynvah have biosimilar risk?
No. Biosimilar rules apply to biologic products. Orlynvah is a chemically synthesized small-molecule combination product.
Could Orlynvah be used for complicated UTI?
Not under its current FDA-approved label. Treatment of complicated UTI or other resistant bacterial infections would require supporting clinical evidence and FDA approval for the relevant indication.
References
- U.S. Food and Drug Administration. (2024). Orlynvah (sulopenem etzadroxil and probenecid) prescribing information.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- Iterum Therapeutics plc. (2024). New drug application and clinical development materials for sulopenem etzadroxil and probenecid.
- U.S. Food and Drug Administration. (2024). Pivya (pivmecillinam) prescribing information.
- Iterum Therapeutics plc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certifications and 30-month stay provisions.
